Tumor flare after start of RAF inhibition in KRAS mutated NSCLC: a case report.
Lung Cancer
; 87(2): 201-3, 2015 Feb.
Article
em En
| MEDLINE
| ID: mdl-25488861
ABSTRACT
Here we describe a case of striking tumor flare after start of treatment with sorafenib and metformin as part of a phase II clinical trial. Previous reports have described a paradoxal activation of the MAPK pathway after treatment with a weak RAF inhibitor. This mechanism is based on inhibition of a negative feedback loop to upstream effectors of RAF and subsequently increased stimulation of the RAS-RAF-MEK-ERK (MAPK) pathway. We suggest that sorafenib may contribute to tumor progression through this mechanism and clinicians should be aware of this phenomenon when treating NSCLC patients with sorafenib.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Proteínas ras
/
Proteínas Proto-Oncogênicas B-raf
/
Inibidores de Proteínas Quinases
/
Neoplasias Pulmonares
/
Mutação
Limite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Lung Cancer
Assunto da revista:
NEOPLASIAS
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Holanda